Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 406.99 -0.15% -0.61
REGN closed down 0.15 percent on Tuesday, March 19, 2019, on 86 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical REGN trend table...

Date Alert Name Type % Chg
Mar 19 NR7 Range Contraction 0.00%
Mar 18 Fell Below 50 DMA Bearish -0.15%
Mar 15 Crossed Above 50 DMA Bullish -1.80%
Mar 15 Pocket Pivot Bullish Swing Setup -1.80%
Mar 14 MACD Bearish Centerline Cross Bearish -0.13%
Mar 14 NR7 Range Contraction -0.13%
Mar 13 Fell Below 50 DMA Bearish -0.49%
Mar 12 50 DMA Support Bullish -2.55%
Mar 12 Oversold Stochastic Weakness -2.55%
Mar 11 Crossed Above 50 DMA Bullish -1.23%

Older signals for REGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Medicine Health Biotechnology Biopharmaceutical Pain Immunology Infectious Diseases Antibodies Monoclonal Antibodies Inflammation Disorders Rheumatoid Arthritis Cardiovascular Diseases Atopic Dermatitis Macular Edema Sanofi Breakthrough Therapy Aflibercept Allergic Asthma Immune Diseases Metastatic Colorectal Cancer Regeneron
Is REGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 442.0
52 Week Low 281.89
Average Volume 716,725
200-Day Moving Average 378.3897
50-Day Moving Average 415.1602
20-Day Moving Average 419.7965
10-Day Moving Average 411.115
Average True Range 9.7264
ADX 15.64
+DI 20.0966
-DI 24.2867
Chandelier Exit (Long, 3 ATRs ) 412.8208
Chandelier Exit (Short, 3 ATRs ) 429.0792
Upper Bollinger Band 441.4089
Lower Bollinger Band 398.1841
Percent B (%b) 0.2
BandWidth 10.296608
MACD Line -1.6878
MACD Signal Line 0.8019
MACD Histogram -2.4897
Fundamentals Value
Market Cap 43.15 Billion
Num Shares 106 Million
EPS 9.97
Price-to-Earnings (P/E) Ratio 40.82
Price-to-Sales 8.43
Price-to-Book 7.99
PEG Ratio 1.55
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 414.97
Resistance 3 (R3) 414.99 412.36 413.64
Resistance 2 (R2) 412.36 410.32 412.35 413.20
Resistance 1 (R1) 409.67 409.07 408.36 409.65 412.75
Pivot Point 407.04 407.04 406.38 407.03 407.04
Support 1 (S1) 404.35 405.00 403.04 404.33 401.23
Support 2 (S2) 401.72 403.75 401.71 400.78
Support 3 (S3) 399.03 401.72 400.34
Support 4 (S4) 399.01